patent semaglutide Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Indian generics undercut Wegovy by

Metabolites are the products of enzyme-catalyzed reactions that occur naturally within cells

Biologic complexity: Unlike small-molecule drugs, semaglutide is a biologic, meaning any generic version would likely be a biosimilar, which involves a more complicated manufacturing process that is highly regulated and more expensive than manufacturing generic drugs

This flexibility allows for a more personalized and tolerable treatment experience

The drug was approved for chronic weight management in adults with obesity or overweight conditions

Eli Lilly followed with Zepbound in November 2023

It is presumed that vitamin B supplements may have contributed to obesity development levels